High prevalence of chronic conditions has been a key driver of healthcare costs in the United States, and Medicaid beneficiaries tend to have higher rates of chronic diseases than people not on Medicaid.
High prevalence of chronic conditions has been a key driver of healthcare costs in the United States, and Medicaid beneficiaries tend to have higher rates of chronic diseases than people not on Medicaid.
A new review published in American Journal of Preventive Medicine examined studies published between 2000 and 2016 to estimate the prevalence and cost of noncommunicable chronic diseases in Medicaid.
“As the Medicaid population continues to change, it is increasingly important to understand the major health burdens this population faces and the associated medical costs, which is important for informing future program design and developing health promotion programs to contain or reduce the public health burden and healthcare costs,” the authors explained.
The review looked at adults between the ages of 18 and 64 years and, based on the 29 studies selected, reported the following prevalence estimates:
The review presented the total cost per patient with disease and the disease-related cost per patient with disease separately. For total cost per patient, heart failure/congestive heart failure ($29,271 to $51,937) and cancer ($29,384 to $46,194) were the most expensive. However, in the disease-related cost category, congenital heart disease ($5835), heart failure/congestive heart failure ($7031), and chronic obstructive pulmonary disease (COPD) ($3968 to $6491) were the most expensive based on the studies reviewed.
In general, Medicaid beneficiaries have a high prevalence of heart diseases. Hypertension, hyperlipidemia, heart disease, and diabetes were common comorbidities. The review also found that patients with COPD had high rates of hypertension and diabetes.
The authors did acknowledge some limitations, such as many studies using state-level data, which is important since states’ Medicaid populations can vary. In addition, the use of claims data in many of the studies in the review might undercount the number of patients with certain chronic conditions. Despite the limitations, the review confirms the high prevalence of noncommunicable chronic diseases among Medicaid beneficiaries.
“The specific prevalence and cost estimates highlighted here could be used to inform the evaluation of interventions for effectively managing chronic diseases and controlling costs in this vulnerable population and for informing future designs of the Medicaid program,” the authors concluded.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Study: Decreased BMI Increases Severe Exacerbation, All-Cause Mortality Risk in Patients With COPD
April 10th 2024Decreased body mass index (BMI) in patients with chronic obstructive pulmonary disease (COPD) was linked to a higher risk of severe exacerbations and all-cause mortality, emphasizing the importance of monitoring BMI for managing COPD and predicting outcomes.
Read More
A Pulmonologist on Why You Should Think About Respiratory Health and the Lungs
November 16th 2021On this episode of Managed Care Cast, we speak with MeiLan K. Han, MD, MS, the author of a book released this month called Breathing Lessons: A Doctor’s Guide to Lung Health. Han, a pulmonologist, gives an inside tour of the lungs and how they work, zooms out to examine the drivers of poor respiratory health, and addresses policy changes that are needed to improve lung health.
Listen
Dose-Escalation, Low-Dose Regimens May Improve Roflumilast Treatment Adherence in Patients With COPD
March 24th 2024This study suggests that dose-escalation or low-dose regimens for roflumilast treatment in patients with chronic obstructive pulmonary disease (COPD) may improve adherence.
Read More